Mark Peterson

A partnership with UTMB to deploy rapid Lassa fever diagnostics in West Africa is more than a public health play; it's a high-stakes field test for the future of portable molecular labs.

A new $18.7M initiative isn't just a health campaign; it's a calculated investment to reverse Oklahoma's dire health stats and boost its economic future.

With Idaho facing a severe behavioral health crisis, Icarus Wellness's new leader signals a strategic shift towards integrated, continuous care to capture a critical market.

Marion Munley's elevation to AAJ President-Elect isn't just a career milestone; it's a strategic maneuver signaling a more aggressive, specialized fight ahead.

The addition of a top international tax expert is more than a personnel move; it's the first major signal of how TPG's capital is arming Smith + Howard for a national expansion.

With a $7.25M seed round led by Fifth Wall, Antares Labs is ditching 'bolt-on' AI for a radical new model: building a custom brain inside real estate giants.

Two clean energy titans, California and Rajasthan, are bypassing national politics to tackle grid challenges, setting a new playbook for global cooperation.

Fairtility's expanded AI partnership with First Fertility isn't just a tech deployment. It's a key signal that the battle for dominance in the fertility market is shifting to a new trifecta: operational scale, data-driven precision, and a radically transparent patient experience.

Hasbro is taking My Little Pony digital-first. A deep dive into the YouTube-exclusive series and what it signals about the toy giant's IP empire.

As Amwell prepares its Q2 report, the focus shifts from growth-at-all-costs to a disciplined platform strategy. Is this the blueprint for survival?

Jaipur's Raydean Enterprises is no longer just a parts maker. A new fundraise reveals its strategy to dominate India's energy value chain from solar to grid.

A hefty Ps. 1.2 billion distribution is more than just a dividend; it's a clear signal of Mexico's nearshoring boom and FIBRA Prologis's market mastery.

A slight revenue dip masks Robertet’s masterful navigation of a split market, with strategic investments in fragrance and emerging economies paying off handsomely.

Taiwan's Jyong Biotech touts a global licensing strategy for its BPH drug, but a closer look reveals significant clinical setbacks and financial pressures.

RTM Engineering's expansion into Northwest Arkansas, led by M&A veteran David Leiffer, isn't just a new office—it's a calculated bet on a regional boom.

The 2026 JUNO Awards generated a record $17.2M for Hamilton. The real story is the city's strategic pivot to a culture-driven economic model.

A compressed calendar of central bank decisions from the Fed, ECB, and BoE is set to collide with geopolitical risk, creating a perfect storm of volatility.

AcroCyte Therapeutics secures funding from the US government's 'DARPA for Health,' validating its unique organoid tech and signaling a strategic push to solve organ shortages.

A new $1,000 scholarship seems minor, but it's a strategic signal about the future of medical leadership and the high cost of entry into healthcare.

CoAspire's Navy deal signals a major shift. A bootstrapped firm using 3D printing to build affordable cruise missiles is challenging the defense establishment.